Gaboxadol
Experimental extrasynaptic GABA-A agonist (super-agonist at delta-subunit receptors) once developed as a hypnotic that enhanced slow-wave sleep. Development for insomnia was halted in 2007 over efficacy and psychiatric/perceptual adverse effects; later revived in a rare-disease programme.
01 Overview
Gaboxadol (THIP, formerly proposed brand Lunesta's rival) is a selective agonist at extrasynaptic delta-subunit-containing GABA-A receptors. Unlike benzodiazepines and Z-drugs, which act at the synaptic benzodiazepine site, gaboxadol enhances tonic inhibition and notably increased slow-wave (deep) sleep in trials, generating interest as a fundamentally different hypnotic.
Merck and Lundbeck ended the insomnia programme in 2007 after Phase III data showed limited efficacy and dose-related adverse effects including disorientation, hallucinations, and euphoria, with abuse-liability signals at higher doses. It was never approved as a hypnotic. The molecule was later repurposed (as OV101/gaboxadol) for investigation in Angelman and Fragile X syndromes. It remains an experimental agent, not a marketed sleep drug.
02 Mechanism
Selective agonist at extrasynaptic delta-subunit GABA-A receptors, enhancing tonic inhibitory conductance and increasing slow-wave sleep, distinct from the synaptic benzodiazepine-site mechanism of Z-drugs.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Trial (insomnia, historical) | 5–15 mg/day | Oral | Doses of 10-15 mg were studied for sleep; higher doses drove adverse effects. Not an approved or recommended regimen. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased slow-wave (deep) sleepEnhanced deep-sleep EEG activity in trials, distinguishing it mechanistically from Z-drugs. | Clinical | ||
| Reduced wake after sleep onsetSome improvement in sleep maintenance in early studies. | modest in trials | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Euphoria / abuse-liability signalEuphoria and drug-liking reported at supratherapeutic doses in abuse-liability studies. | Moderate | Seen at higher doses | Clinical | |
| Perceptual disturbances / hallucinationsDisorientation, hallucinations, and unusual perceptual experiences, especially at higher doses. | Severe | Dose-related in trials | Clinical |